Literature DB >> 14609269

Experimental infection of calves with bovine viral diarrhoea virus type-2 (BVDV-2) isolated from a contaminated vaccine.

E Falcone1, P Cordioli, M Tarantino, M Muscillo, G Sala, G La Rosa, I L Archetti, C Marianelli, G Lombardi, M Tollis.   

Abstract

A non-cytopathic strain of BVDV-2 was isolated from a batch of live infectious bovine rhinotracheitis (IBR) vaccine, and inoculated intranasally into four 3-month-old calves. Severe signs of disease developed by days 4 and 6 in three of the calves, free of BVDV and antibodies to BVDV, that had been exposed to the virus. These calves survived the acute phase of the infection and progressively recovered. BVDV was consistently isolated, or the respective viral RNA was detected, in the buffy coats from blood samples collected starting from days 2 or 4 up to days 11 or 14 after the experimental infection. Viral RNA was also detected in sera from these infected calves until the presence in the serum of virus neutralizing antibodies was demonstrated. By contrast, the only calf having pre-existing neutralizing antibodies to BVDV at the start of the study was protected from the disease. No virus was detected at any time after experimental inoculation of this calf. Genomic characterization of the BVDV-2 isolated in cell cultures, or detected in sera from the experimentally infected animals, revealed 100%, homology in the nucleotide sequence with the BVDV-2 detected as a contaminant of the live IBR virus vaccine. These findings provided evidence of the infective nature of the contaminant BVDV-2 and of its potential to generate disease outbreaks when inoculated into susceptible animals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609269     DOI: 10.1023/a:1026064603630

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  29 in total

1.  Genotyping of bovine viral diarrhoea viruses isolated from cattle in northern Italy.

Authors:  E Falcone; P Cordioli; G Sala; M Tarantino; M Tollis
Journal:  Vet Res Commun       Date:  2001-02       Impact factor: 2.459

2.  Neutralizing antibodies to type 1 and 2 bovine viral diarrhea viruses: detection by inhibition of viral cytopathology and infectivity by immunoperoxidase assay.

Authors:  R W Fulton; J T Saliki; L J Burge; J M d'Offay; S R Bolin; R K Maes; J C Baker; M L Frey
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

3.  Serologic evaluation of five unvaccinated heifers to detect herds that have cattle persistently infected with bovine viral diarrhea virus.

Authors:  Roxanne B Pillars; Daniel L Grooms
Journal:  Am J Vet Res       Date:  2002-04       Impact factor: 1.156

4.  [Outbreak of bovine virus diarrhea on Dutch dairy farms induced by a bovine herpesvirus 1 marker vaccine contaminated with bovine virus diarrhea virus type 2].

Authors:  H W Barkema; C J Bartels; L van Wuijckhuise; J W Hesselink; M Holzhauer; M F Weber; P Franken; P A Kock; C J Bruschke; G M Zimmer
Journal:  Tijdschr Diergeneeskd       Date:  2001-03-15

5.  Methods for detection and frequency of contamination of fetal calf serum with bovine viral diarrhea virus and antibodies against bovine viral diarrhea virus.

Authors:  S R Bolin; P J Matthews; J F Ridpath
Journal:  J Vet Diagn Invest       Date:  1991-07       Impact factor: 1.279

Review 6.  The clinical manifestations of bovine viral diarrhea infection.

Authors:  J C Baker
Journal:  Vet Clin North Am Food Anim Pract       Date:  1995-11       Impact factor: 3.357

7.  Severe disease in adult dairy cattle in three UK dairy herds associated with BVD virus infection.

Authors:  G P David; T R Crawshaw; R F Gunning; R C Hibberd; G M Lloyd; P R Marsh
Journal:  Vet Rec       Date:  1994-04-30       Impact factor: 2.695

8.  Identification of a new group of bovine viral diarrhea virus strains associated with severe outbreaks and high mortalities.

Authors:  C Pellerin; J van den Hurk; J Lecomte; P Tijssen
Journal:  Virology       Date:  1994-09       Impact factor: 3.616

9.  Molecular cloning and nucleotide sequence of the pestivirus bovine viral diarrhea virus.

Authors:  M S Colett; R Larson; C Gold; D Strick; D K Anderson; A F Purchio
Journal:  Virology       Date:  1988-07       Impact factor: 3.616

10.  Assessment of protection from systemic infection or disease afforded by low to intermediate titers of passively acquired neutralizing antibody against bovine viral diarrhea virus in calves.

Authors:  S R Bolin; J F Ridpath
Journal:  Am J Vet Res       Date:  1995-06       Impact factor: 1.156

View more
  4 in total

1.  Dendritic Cell Targeting of Bovine Viral Diarrhea Virus E2 Protein Expressed by Lactobacillus casei Effectively Induces Antigen-Specific Immune Responses via Oral Vaccination.

Authors:  Yixin Wang; Baohua Feng; Chao Niu; Shuo Jia; Chao Sun; Zhuo Wang; Yanping Jiang; Wen Cui; Li Wang; Yigang Xu
Journal:  Viruses       Date:  2019-06-25       Impact factor: 5.048

2.  Experimental infection of cattle, sheep and pigs with 'Hobi'-like pestivirus.

Authors:  Nicola Decaro; Viviana Mari; Maria Stella Lucente; Rossana Sciarretta; Ana Moreno; Carlo Armenise; Michele Losurdo; Michele Camero; Eleonora Lorusso; Paolo Cordioli; Canio Buonavoglia
Journal:  Vet Microbiol       Date:  2011-09-03       Impact factor: 3.293

3.  Detection and genotyping of bovine viral diarrhea virus found contaminating commercial veterinary vaccines, cell lines, and fetal bovine serum lots originating in Mexico.

Authors:  Ninnet Gómez-Romero; Lauro Velazquez-Salinas; Julia F Ridpath; Antonio Verdugo-Rodríguez; Francisco Javier Basurto-Alcántara
Journal:  Arch Virol       Date:  2021-05-10       Impact factor: 2.574

4.  Immunogenicity evaluation of recombinant Lactobacillus casei W56 expressing bovine viral diarrhea virus E2 protein in conjunction with cholera toxin B subunit as an adjuvant.

Authors:  Shuo Jia; Xinning Huang; Hua Li; Dianzhong Zheng; Li Wang; Xinyuan Qiao; Yanping Jiang; Wen Cui; Lijie Tang; Yijing Li; Yigang Xu
Journal:  Microb Cell Fact       Date:  2020-10-01       Impact factor: 6.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.